Benzodiazepine Use Is Associated With an Increased Risk of Neurocognitive Impairment in People Living With HIV

被引:12
|
作者
Saloner, Rowan [1 ,2 ]
Grelotti, David J. [1 ]
Tyree, Griffin [1 ]
Sundermann, Erin E. [1 ]
Ma, Qing [3 ]
Letendre, Scott [1 ]
Heaton, Robert K. [1 ]
Cherner, Mariana [1 ]
机构
[1] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[2] San Diego State Univ Univ Calif San Diego, Joint Doctoral Program Clin Psychol, San Diego, CA USA
[3] SUNY Buffalo, Dept Pharm Practice, Buffalo, NY USA
关键词
benzodiazepines; neuroHIV; HIV-associated neurocognitive disorders; executive functions; memory; processing speed; ADULTS; DYSFUNCTION; WITHDRAWAL; DISORDERS; ADHERENCE; ACCIDENTS; MEMORY; BRAIN;
D O I
10.1097/QAI.0000000000002183
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: Despite potential for dependence and adverse neurological effects, long-term benzodiazepine (BZD) use is common among people living with HIV (PLWH). As PLWH are at risk for central nervous system dysfunction, we retrospectively examined the association between BZD use and HIV-associated neurocognitive impairment (NCI). Methods: Three hundred six PLWH underwent comprehensive neurobehavioral evaluations. Current BZD use (BZD+) was determined through self-report. Using propensity scores, 153 BZD+ individuals were matched to 153 BZD+ participants on demographics and medical comorbidities. Multiple regression models examined NCI and demographically adjusted neurocognitive T-scores as a function of BZD status, adjusting for estimated premorbid ability, current affective symptoms, and nadir CD4 count. Secondary analyses explored neurocognitive correlates of positive BZD urine toxicology screens (TOX+) and specific BZD agents. Results: Median duration of BZD use was 24 months. Current BZD use related to higher likelihood of NCI (odds ratio = 2.13, P = 0.003) and poorer global (d = -0.28, P = 0.020), processing speed (d = -0.23, P = 0.047), and motor T-scores (d = -0.32, P = 0.008). Compared with BZD-/TOX-, BZD+/TOX+ exhibited additional decrements in executive function (d = -0.48, P = 0.013), working memory(d = -0.49, P = 0.011), and delayed recall (d = -041, P = 0.032). For individual agents, diazepam, lorazepam, and alprazolam were most strongly associated with NCI (odds ratios >2.31). Discussion: BZD use may elevate risk for NCI in PLWH, potentially through diffuse neurocognitive slowing and acute compromise of recall and higher-order capacities. These effects are robust to psychosocial and HIV-specific factors and occur in comparison with a tightly matched BZD- group. Prospective and interventional studies should evaluate causal associations between NCI and BZD use and explore treatment alternatives to BZDs in PLWH.
引用
收藏
页码:475 / 482
页数:8
相关论文
共 50 条
  • [1] Benzodiazepine Use Is Associated with an Increased Risk for HIV-Associated Neurocognitive Disorders
    Saloner, R.
    Tyree, G.
    Grelotti, D.
    Ma, Q.
    Letendre, S.
    Heaton, R.
    Cherner, M.
    [J]. ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2019, 34 (06) : 951 - 951
  • [2] The association between benzodiazepine use and greater risk of neurocognitive impairment is moderated by medical burden in people with HIV
    Sundermann, Erin E.
    Saloner, Rowan
    Rubtsova, Anna
    Nguyen, Annie L.
    Letendre, Scott
    Moore, Raeanne C.
    Cherner, Mariana
    Ma, Qing
    Marquine, Maria J.
    [J]. JOURNAL OF NEUROVIROLOGY, 2022, 28 (03) : 410 - 421
  • [3] The association between benzodiazepine use and greater risk of neurocognitive impairment is moderated by medical burden in people with HIV
    Erin E. Sundermann
    Rowan Saloner
    Anna Rubtsova
    Annie L. Nguyen
    Scott Letendre
    Raeanne C. Moore
    Mariana Cherner
    Qing Ma
    María J. Marquine
    [J]. Journal of NeuroVirology, 2022, 28 : 410 - 421
  • [4] Benzodiazepine Use and HIV-Associated Neurocognitive Impairment: Which Comes First?
    Mantovani, Elisa
    Lugoboni, Fabio
    Federico, Angela
    Zipeto, Donato
    Tamburin, Stefano
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 83 (04) : E26 - E27
  • [5] Exploring substance use and HIV treatment factors associated with neurocognitive impairment among people living with HIV/AIDS
    Attonito, Jennifer M.
    Devieux, Jessy G.
    Lerner, Brenda D. G.
    Hospital, Michelle M.
    Rosenberg, Rhonda
    [J]. FRONTIERS IN PUBLIC HEALTH, 2014, 2
  • [6] Cannabis Exposure is Associated With a Lower Likelihood of Neurocognitive Impairment in People Living With HIV
    Watson, Caitlin Wei-Ming
    Paolillo, Emily W.
    Morgan, Erin E.
    Umlauf, Anya
    Sundermann, Erin E.
    Ellis, Ronald J.
    Letendre, Scott
    Marcotte, Thomas D.
    Heaton, Robert K.
    Grant, Igor
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 83 (01) : 56 - 64
  • [7] Risk Factors of Asymptomatic Neurocognitive Impairment in People Living with HIV in an Indian Cohort
    Gupta, Salil
    Venugopal, Nirmala
    [J]. JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2020, 11 (02) : 230 - 236
  • [8] Gut Microbiota Dysbiosis Is Not Independently Associated With Neurocognitive Impairment in People Living With HIV
    Zhang, Fengdi
    Yang, Junyang
    Ji, Yongjia
    Sun, Meiyan
    Shen, Jiayin
    Sun, Jianjun
    Wang, Jiangrong
    Liu, Li
    Shen, Yinzhong
    Zhang, Renfang
    Chen, Jun
    Lu, Hongzhou
    [J]. FRONTIERS IN MICROBIOLOGY, 2019, 9
  • [9] An overview of neurocognitive impairment in older people living with HIV
    Ng, Rachel Q. M.
    Yip, K. F.
    Teh, Y. E.
    [J]. PROCEEDINGS OF SINGAPORE HEALTHCARE, 2023, 32
  • [10] HIV-associated neurocognitive impairment in stable people living with HIV on ART in rural Tanzania
    Sanmarti, M.
    Meyer, A. C.
    Jaen, A.
    Robertson, K.
    Tan, N.
    Mapesi, H.
    Samson, L.
    Ndaki, R.
    Battegay, M.
    Tanner, M.
    Weisser, M.
    Dalmau, D.
    Letang, E.
    [J]. HIV MEDICINE, 2021, 22 (02) : 102 - 112